Aroa Biosurgery Ltd
ASX:ARX

Watchlist Manager
Aroa Biosurgery Ltd Logo
Aroa Biosurgery Ltd
ASX:ARX
Watchlist
Price: 0.74 AUD 8.82%
Market Cap: 255.2m AUD
Have any thoughts about
Aroa Biosurgery Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

-26.9
Current
-31.6
Median
4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-26.9
=
Enterprise Value
240.8m AUD
/
EBIT
-9.9m NZD
All Countries
Close
Market Cap EV/EBIT
NZ
Aroa Biosurgery Ltd
ASX:ARX
255.2m AUD -26.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 673.3
US
Abbvie Inc
NYSE:ABBV
318.1B USD 23.9
US
Amgen Inc
NASDAQ:AMGN
142.2B USD 30.5
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD 22.7
US
Epizyme Inc
F:EPE
94.1B EUR -499.5
AU
CSL Ltd
ASX:CSL
135.7B AUD 24.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 17.1
US
Seagen Inc
F:SGT
39.3B EUR -52.9
NL
argenx SE
XBRU:ARGX
36.2B EUR -79.9
EBIT Growth EV/EBIT to Growth
NZ
Aroa Biosurgery Ltd
ASX:ARX
Average EV/EBIT: 21.5
Negative Multiple: -26.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 673.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.9
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.5
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.5 N/A N/A
AU
CSL Ltd
ASX:CSL
24.7
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.9 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-365.3
2-Years Forward
EV/EBIT
39.7
3-Years Forward
EV/EBIT
14.8

See Also

Discover More